Targeting the gut and tumor microbiota in cancer

Elizabeth M Park; Manoj Chelvanambi; Neal Bhutiani; Guido Kroemer; Laurence Zitvogel; Jennifer A Wargo

doi:10.1038/s41591-022-01779-2

Targeting the gut and tumor microbiota in cancer

Nat Med. 2022 Apr;28(4):690-703. doi: 10.1038/s41591-022-01779-2. Epub 2022 Apr 19.

Authors

Elizabeth M Park^{1

2}, Manoj Chelvanambi², Neal Bhutiani², Guido Kroemer^{3

4

5

6}, Laurence Zitvogel^{7

8

9

10}, Jennifer A Wargo^{11

12}

Affiliations

¹ Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Université de Paris, Inserm CIC 1417, I-Reivac, APHP, Hopital Cochin, Paris, France.
⁴ Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le Cancer, Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
⁵ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France.
⁶ Pôle de Biologie, Hôpital Européen George Pompidou, Assistance Publique - Hôpitaux de Paris, Paris, France.
⁷ Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.
⁸ Gustave Roussy, Villejuif, France.
⁹ Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy, Villejuif, France.
¹⁰ Center of Clinical Investigations BIOTHERIS, INSERM CIC1428, Gustave Roussy, Villejuif, France.
¹¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
¹² Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

PMID: 35440726
DOI: 10.1038/s41591-022-01779-2

Abstract

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy. Our understanding of the complex relationship between different host-intrinsic microorganisms, as well as the multifaceted mechanisms by which they influence health and disease, has grown tremendously-hastening development of novel therapeutic strategies that target the microbiota to improve treatment outcomes in cancer. Accordingly, the evaluation of a patient's microbial composition and function and its subsequent targeted modulation represent key elements of future multidisciplinary and precision-medicine approaches. In this Review, we outline the current state of research toward harnessing the microbiome to better prevent and treat cancer.

Publication types

Review
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Gastrointestinal Microbiome* / physiology
Humans
Immunotherapy
Microbiota*
Neoplasms* / pathology
Neoplasms* / therapy
Precision Medicine